

RECEIVED  
CENTRAL FAX CENTER  
JUN 07 2007

COOPER & DUNHAM LLP  
ATTORNEYS AT LAW

1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036  
TELEPHONE: (212) 278-0400

CHRISTOPHER C. DUNHAM  
NORMAN M. ZIVIN  
JOHN P. WHITE  
ROBERT D. HOROWITZ  
ERIC D. KIRSCH  
GARY J. GERSHNIK  
WENDY E. MILLER  
ROBERT T. MALDONADO  
MARIA V. MARUCCI  
JEFFREY C. BIEH  
TONIA A. SAYOUR  
ASHOK K. CHANDRA\*  
LISA E. HORWITZ\*

IVAN G. KAVRUKOV  
PETER D. MURRAY  
WILLIAM E. FELTON  
ROBERT D. KATZ  
PAUL TENO  
PETER J. PHILLIPS  
RICHARD S. MILNER  
RICHARD F. JAWORSKI  
ALDE GERSPACHER  
BRIAN J. AMOS  
GREGORY J. CARBO  
JOSEPH A. SHERINGKY\*  
HINDY R. DYM\*

FACSIMILE: (212) 391-0525  
(212) 391-0526  
(212) 391-0630  
(212) 391-0631  
(212) 827-0247

SCIENTIFIC ADVISOR  
JAMES R. MAJOR, D. PHIL.  
AMANDA L. WILLIS, PH.D.

FOUNDED 1897  
www.cooperdunham.com

FACSIMILE TRANSMISSION

\*NEW YORK STATE BAR ADMISSION PENDING

PLEASE DELIVER THE FOLLOWING PAGES

TO : Commissioner of Patents

COMPANY/FIRM : USPTO

FACSIMILE NO. : 1-571-273-8300

FROM : John P. White

TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 83

DATE : June 7, 2007 TIME: 3.45pm

CLIENT/DOCKET: 1769/41426-GC

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (212) 278-0410.

Re: U.S. Serial No. 10/614,625

=====

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY BE AN ATTORNEY-CLIENT COMMUNICATION CONTAINING INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

RECEIVED  
CENTRAL FAX CENTER

JUN 07 2007

Dkt. 41426-GC/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren D.W. Heston et al.  
Serial No.: 10/614,625 Group Art Unit: 1649  
Filed: July 2, 2003 Examiner: C. Borgeest  
For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND  
USES THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
June 7, 2007

BY FACSIMILE

1-571-273-8300  
Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on the PTO-1449 form attached hereto as (Exhibit A), and copies of which are attached hereto as Exhibits 1-8.

1. Elgamal et al., (2000), Abstract, Semin. Surg. Oncol, 18:10-6; (Exhibit 1)
2. Abraham et al., (1990), Folate Analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 hepatoma cells, J. Med. Chem., 33(2):711-717; (Exhibit 2)
3. Whitehead et al., (1992), Accumulation of high levels of methotrexate polyglutamates in

Applicants: Warren D.W. Heston, et al.  
Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 2 of 4

lymphoblasts from children with hyperdiploid (>50 chromosomes) B-Lineage acute lymphoblastic leukemia: a pediatric oncology group study, Blood 80(5):1316-1323; (Exhibit 3)

4. Ghosh Arundhati et al., (2005), Novel role of prostate-Specific membrane antigen in suppressing prostate cancer invasiveness, Cancer Research, 65(3):727-731; (Exhibit 4)
5. Tasch et al., (2001), A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?, Crit. Rev. in Immunol., 21(1-3):249-261; (Exhibit 5)
6. Heston, W., (1996), Bedeuteng des prostataspezifischen membranantigens (PSMA), Urologe Ausgabe A, 35(5):400-407; (Exhibit 6)
7. English language translation of Heston, W., (1996), Bedeuteng des prostataspezifischen membranantigens (PSMA), Urologe Ausgabe A, 35(5):400-407; (Exhibit 7)
8. Extended Search Report and European Search Opinion issued March 28, 2007 in connection with European Application No. 06002339.7; (Exhibit 8)

Items 2-6 were cited in an Extended Search Report and European Search Opinion issued March 28, 2007 in connection with European Application No. 06002339.7. The Extended Search Report and European Search Opinion are listed hereinabove as item 8, and a copy is attached hereto as Exhibit 8.

Applicants: Warren D.W. Heston, et al.  
Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 3 of 4

Applicants note that item no. 6 is a German language article. In accordance with 37 C.F.R. §1.98(a)(3)(ii) applicants attach hereto as Exhibit 7 an English language translation of item 6.

Applicants note that WO 94/09820 A; Abdel-Nabi et al. (1992); and Israeli R.S. et al. (1993) as listed in item 8 (Exhibit 8) were previously disclosed to the U.S. Patent and Trademark Office in an Information Disclosure Statement filed March 26, 2004 in connection with the above-identified application.

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c)(2) and authorization is hereby given to charge the amount of amount of ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) to Deposit Account No. 03-3125.


Applicants request that the Examiner consider the items listed and make them of record in the subject application. If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


Applicants: Warren D.W. Heston, et al.  
Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 4 of 4

No fee, other than the enclosed \$180.00 Information Disclosure Statement fee, is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement.

However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being transmitted by facsimile on the date listed below to 1-571-273-8300, Commissioner for Patents, Alexandria, VA 22313-1450	
 John P. White Reg. No. 28,678	6/7/07 Date

  
John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

# EXHIBIT A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Application Number	10/614,625
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Filing Date	July 2, 2003
				First Named Inventor	Warren D.W. Heston et al.
				Art Unit	1649
				Examiner Name	C. Borgeest
				Attorney Docket No.	41426- GC/JPW/BJA
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		Elgamal et al., (2000), Abstract, Semin. Surg. Oncol, 18:10-6			
		Abraham et al., (1990), Folate Analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 hepatoma cells, J. Med. Chem., 33(2):711-717			
		Whitehead et al., (1992), Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-Lineage acute lymphoblastic leukemia: a pediatric oncology group study, Blood 80(5):1316-1323			
		Ghosh Arundhati et al., (2005), Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness, Cancer Research, 65(3):727-731			
		Tasch et al., (2001), A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?, Crit. Rev. in Immunol., 21(1-3):249-261			
		Heston, W., (1996), Bedeuteng des prostataspezifischen membranantigens (PSMA), Urologe Ausgabe A, 35(5):400-407			
		English language translation of Heston, W., (1996), Bedeuteng des prostataspezifischen membranantigens (PSMA), Urologe Ausgabe A, 35(5):400-407			
		Extended Search Report and European Search Opinion issued March 28, 2007 in connection with European Application No. 06002339.7			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p>					

Applicants: Warren D.W. Heston et al.  
U.S. Serial No. 10/614,625  
Filed: June 6, 1995  
Exhibit A

## EXHIBIT 1